or Try an Advanced Search...

    Protein Kinase Inhibitor Stocks List

    Symbol Grade Name % Change
    ALLR F Allarity Therapeutics, Inc. -1.07
    ACLX D Arcellx, Inc. 2.07
    AVBP C ArriVent BioPharma, Inc. 3.33
    BPMC C Blueprint Medicines Corporation -0.14
    BBIO C BridgeBio Pharma, Inc. 3.57
    COGT D Cogent Biosciences, Inc. -3.24
    CRIS D Curis, Inc. -3.08
    DAWN C Day One Biopharmaceuticals, Inc. -2.38
    DCPH A Deciphera Pharmaceuticals, Inc. 0.00
    ELVN C Enliven Therapeutics, Inc. -0.79
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Biopharmaceutical Tyrosine Kinase Tyrosine Kinase Receptors Drugs Enzymes Gastrointestinal Gastrointestinal Stromal Tumor Mastocytosis Solid Tumors Systemic Mastocytosis Antineoplastic Drugs Biotechnology Cancer Treatment Clinical Development Clinical Medicine Fibroblast Growth Factor Receptor Gastrointestinal Stromal Tumors Lung Cancer Medicine

    Related ETFs - A few ETFs which own one or more of the above listed Protein Kinase Inhibitor stocks.

    Symbol Grade Name Weight
    CNCR D Loncar Cancer Immunotherapy ETF 8.92
    BBP C BioShares Biotechnology Products Fund 7.26
    IDNA B iShares Genomics Immunology and Healthcare ETF 5.24
    XBI C SPDR S&P Biotech ETF 4.73
    WDNA C WisdomTree BioRevolution Fund 4.46
    View all Protein Kinase Inhibitor ETFs...
    Compare ETFs
    Compare BBP to WDNA Compare CNCR to WDNA Compare IDNA to XBI

        Protein Kinase Inhibitor Stocks Recent News

        Date Stock Title
        May 16 AVBP ArriVent Appoints John Hohneker, M.D., to its Board of Directors
        May 15 ALLR Allarity Therapeutics reports Q1 GAAP EPS of -$22.14
        May 15 ELVN Enliven Therapeutics GAAP EPS of -$0.54 beats by $0.02
        May 14 ELVN Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
        May 14 ALLR Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
        May 14 CRIS Curis Announces Additional Data from TakeAim Leukemia Study
        May 14 BPMC Blueprint Medicines started at buy by Stephens, citing Ayvakit franchise
        May 14 BBIO BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
        May 13 COGT We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth
        May 13 BBIO BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sen...
        May 12 BBIO Cantor picks 14 undervalued biotech stocks worth a second look
        May 12 ACLX Arcellx First Quarter 2024 Earnings: Beats Expectations
        May 10 ACLX Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
        May 10 DCPH Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
        May 10 DCPH Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
        May 10 CRIS Curis to Present Updated Data from the TakeAim Leukemia Study
        May 10 ACLX Arcellx GAAP EPS of -$0.14, revenue of $39.3M
        May 10 ACLX Kite and Arcellx prepare to launch Phase III multiple myeloma trial
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Biopharmaceutical Tyrosine Kinase Tyrosine Kinase Receptors Drugs Enzymes Gastrointestinal Gastrointestinal Stromal Tumor Mastocytosis Solid Tumors Systemic Mastocytosis Antineoplastic Drugs Biotechnology Cancer Treatment Clinical Development Clinical Medicine Fibroblast Growth Factor Receptor Gastrointestinal Stromal Tumors Lung Cancer Medicine
        Protein Kinase Inhibitor

        Protein kinase inhibitors are drugs that block the activity of one or more protein kinases. Protein kinases are enzymes that add phosphate groups to proteins, which can alter their activity and function. Protein kinase inhibitors are used to treat a variety of diseases, including cancer, inflammation, and autoimmune disorders.

        Browse All Tags